Continuum Advisory
AIM icon

Continuum Advisory’s AIM ImmunoTech AIM Stock Holding History

Continuum Advisory’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$88 Hold
500
– – ﹤0.01% 1939
2026
Q2 		$142 Buy
+500
New +$228 ﹤0.01% 1963

Other funds holding AIM

Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Community Bank
Community Bank Dewitt, New York $933M AUM 24.36% 1-Year Est. Return
Harbour Investments
Harbour Investments Madison, Wisconsin $6.75B AUM 16.25% 1-Year Est. Return
Creative Financial Designs
Creative Financial Designs Kokomo, Indiana $2.22B AUM 15.38% 1-Year Est. Return
Hoey Investments
Hoey Investments Coatesville, Pennsylvania $851M AUM 28.55% 1-Year Est. Return

Continuum Advisory's AIM Position: Q3 2026 in Review

Continuum Advisory held its AIM ImmunoTech (AIM) position steady in Q3 2026 at 500 shares worth $88. The position accounts for ﹤0.01% of the portfolio, ranked #1939.

Continuum Advisory first reported a position in AIM in Q2 2026 and has held it in 2 quarters since. The position peaked at $142 in Q2 2026. 15 funds tracked by Wall St. Rank hold AIM as of Q3 2026.

  • Continuum Advisory held 500 shares of AIM ImmunoTech worth $88 as of Q3 2026.
  • Continuum Advisory left its AIM ImmunoTech share count unchanged in Q3 2026.
  • AIM ImmunoTech made up ﹤0.01% of Continuum Advisory's portfolio in Q3 2026, its #1939 holding.
  • Continuum Advisory first reported a position in AIM ImmunoTech in Q2 2026 and has held it in 2 quarters since.
  • Continuum Advisory's AIM ImmunoTech position peaked at $142 in Q2 2026.
  • 15 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q3 2026.

Based on Continuum Advisory's 13F filing for Q3 2026, filed 13 Nov 2026.